Stokes Family Office’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
Other funds holding PFE
VCM
VPM
Stokes Family Office's PFE Position: Q1 2026 in Review
Stokes Family Office reduced its Pfizer (PFE) stake by 7.4% in Q1 2026, selling an estimated $56.7K and leaving 26,587 shares worth $747K. The position accounts for 0.08% of the portfolio, ranked #154.
Stokes Family Office first reported a position in PFE in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.82M in Q4 2021. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Stokes Family Office held 26,587 shares of Pfizer worth $747K as of Q1 2026.
- Stokes Family Office sold 2,131 Pfizer shares in Q1 2026, an estimated $56.7K.
- Pfizer made up 0.08% of Stokes Family Office's portfolio in Q1 2026, its #154 holding.
- Stokes Family Office first reported a position in Pfizer in Q4 2019 and has held it in 26 quarters since.
- Stokes Family Office's Pfizer position peaked at $5.82M in Q4 2021.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Stokes Family Office's 13F filing for Q1 2026, filed 12 May 2026.